William Blair Forecasts NeoGenomics Q1 Earnings

NeoGenomics, Inc. (NASDAQ:NEO) – Stock analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for NeoGenomics in a research report issued to clients and investors on Tuesday, February 18th. William Blair analyst A. Brackmann expects that the medical research company will post earnings per share of $0.00 for the quarter. The consensus estimate for NeoGenomics’ current full-year earnings is ($0.05) per share. William Blair also issued estimates for NeoGenomics’ Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.03 EPS.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million.

Other research analysts have also recently issued reports about the company. Jefferies Financial Group began coverage on NeoGenomics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price objective for the company. Needham & Company LLC reduced their price target on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday. Bank of America reduced their price target on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday. The Goldman Sachs Group reduced their price target on NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Finally, Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.80.

NeoGenomics Trading Down 6.4 %

Shares of NASDAQ:NEO opened at $11.10 on Friday. NeoGenomics has a 52-week low of $10.69 and a 52-week high of $19.11. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -17.90 and a beta of 1.23. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The business has a 50-day moving average price of $15.28 and a 200-day moving average price of $15.49.

Institutional Trading of NeoGenomics

Institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. acquired a new stake in NeoGenomics in the fourth quarter valued at approximately $26,000. Versant Capital Management Inc grew its holdings in NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 1,142 shares during the period. Quarry LP acquired a new stake in NeoGenomics in the third quarter valued at approximately $40,000. Blue Trust Inc. boosted its stake in shares of NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after acquiring an additional 987 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its stake in shares of NeoGenomics by 788.7% in the fourth quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company’s stock worth $61,000 after acquiring an additional 3,289 shares during the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.